Arbutus Biopharma Corp
(NASDAQ:ABUS)
$2.03
0[0.00%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$2.03
0[0.00%]
Open-Close-
Vol / Avg.0 / 591.086KMkt Cap340.140M
Day Range- - -52 Wk Range1.865 - 3.145

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Arbutus Biopharma Stock (NASDAQ:ABUS), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$9.00

Lowest Price Target1

$5.00

Consensus Price Target1

$6.40

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
50000

Analyst Firms Making Recommendations1

  • HC Wainwright & Co.
  • Chardan Capital
  • JMP Securities
  • Jefferies

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Arbutus Biopharma

All Ratings (21)

Upgrades (1)

Downgrades (0)

Initiations (1)

Q

What is the target price for Arbutus Biopharma (ABUS)?

A

The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Arbutus Biopharma (ABUS)?

A

The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

Q

Is the Analyst Rating Arbutus Biopharma (ABUS) correct?

A

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.03, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.